ArticleGenome research2009
Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers.
Article in Genome research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants.iScience · 2026Article
- Epigenetic pioneering by SWI/SNF family remodelers.Molecular cell · 2024Review
- FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nature communications · 2022Article
- A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.Cancer research · 2022Article
- Chromatin Variants Reveal the Genetic Determinants of Oncogenesis in Breast Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Increased FOXA1 levels induce apoptosis and inhibit proliferation in FOXA1-low expressing basal breast cancer cells.American journal of cancer research · 2022Article
- Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.Advances in experimental medicine and biology · 2022Review
- Mechanisms of enhancer action: the known and the unknown.Genome biology · 2021Review
- Analysis of Fox genes in Schmidtea mediterranea reveals new families and a conserved role of Smed-foxO in controlling cell death.Scientific reports · 2021Article
- Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.Nature communications · 2020Article
- Article
- Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.Oncogene · 2019Article
- FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women?Breast cancer research and treatment · 2017Article
- Cytosine modifications modulate the chromatin architecture of transcriptional enhancers.Genome research · 2017Article
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.Science (New York, N.Y.) · 2017Article
- Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer.Genes & diseases · 2015Article
- A novel DNA sequence motif in human and mouse genomes.Scientific reports · 2015Article
- Remodeling of retrotransposon elements during epigenetic induction of adult visual cortical plasticity by HDAC inhibitors.Epigenetics & chromatin · 2015Article
- An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer.Oncogene · 2014Article
- Minireview: pioneer transcription factors in cell fate specification.Molecular endocrinology (Baltimore, Md.) · 2014Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Selective activity of a specific set of enhancers defines tissue-specific gene transcription. The pioneer factor FOXA1 has been shown to induce functional enhancer competency through chromatin openings. We have previously found that FOXA1 is recruited to thousands of regions across the genome of a given cell type. Here, we monitored the chromatin structure at FOXA1 binding sites on a chromosome-wide scale using formaldehyde assisted isolation of regulatory elements (FAIRE). Surprisingly, we find that a significant fraction of FOXA1-bound sites have a relatively closed chromatin conformation linked to a shift of the epigenetic signature toward repressive histone marks. Importantly, these sites are not correlated with gene expression in a given cell type suggesting that FOXA1 is required, but not sufficient, for the functional activity of bound enhancers. Interestingly, we find that a significant proportion of the inactive FOXA1-bound regulatory sites in one cell type are actually functional in another cellular context. We found that at least half of the FOXA1 binding sites from a given cell type are shared with another cell lineage. Mechanisms that restrict the activity of shared FOXA1-bound enhancers likely play a significant role in defining the cell-type-specific functions of FOXA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.